Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of ND-340 in Healthy Volunteers
NCT05588557Phase 1Completed
- Sponsor
- Nang Kuang Pharmaceutical Co., Ltd.
- Start
- Jul 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of ND-340 in postoperative pain (2 arms), sponsored by Nang Kuang Pharmaceutical Co., Ltd. Primary endpoints: Adverse events as assessed by CTCAE v 5.0 up to 140 hours, Changes in 12-lead ECG and Holter monitor up to 140 hours and 9 more. Started Jul 2022; status: completed.
02
Drugs
ND-340
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05588557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05588557.